COVID-19Global NewsNews

Serum Institute, IAVI, Merck to develop COVID-19 treatment

Monoclonal antibodies will be developed to fight COVID-19 and to ensure their prompt and equitable global access

Non-profit scientific research organisation IAVI, vaccine major Serum Institute of India and global science and technology firm Merck have entered into an agreement to develop monoclonal antibodies to fight COVID-19 and to ensure their prompt and equitable global access.

The agreement is “to develop SARS-CoV-2 neutralising monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the Covid-19 pandemic”, the partners said in a statement.

The agreement builds on the advanced antibody discovery and optimisation expertise of International AIDS Vaccine Initiative (IAVI) and Scripps Research, and on Germany’s Merck’s and Serum Institute’s significant capabilities in design and scale up of accelerated manufacturing processes for mAb production, it added.

If the SARS-CoV-2 neutralising antibody candidates being advanced through this partnership are shown to be efficacious in clinical trials, either as a single antibody or a potential combination of both candidates, Merck will lead commercialisation in developed countries, the statement said.

Serum Institute will lead global manufacturing as well as commercialisation in low- and middle-low-income countries, including India, it added.

“We’re acutely aware of the tremendous potential for monoclonal antibodies to be used in Covid-19 response. By combining the scientific achievements of IAVI and Scripps Research with our partners’ development, manufacturing, and distribution expertise, we are hopeful that this partnership will result in globally accessible antibodies that are available to all who can benefit from them,” said Mark Feinberg, President and CEO, IAVI.

On the agreement, Belén Garijo, Vice Chair of the Executive Board and Deputy CEO, Merck said, “Together with IAVI and Serum Institute, we look forward to demonstrating the potential application of these monoclonal antibodies in the management of Covid-19.”

We share a common purpose to accelerate this promising science and deliver effective solutions that address global challenges presented by this pandemic, he added.

“I am pleased that we have joined forces with IAVI and Merck, Darmstadt, Germany in the fight against COVID-19 with the aim of developing monoclonal antibodies for global access,” Adar Poonawalla, CEO, Serum Institute of India said.

Under IAVI’s agreement with Merck and Serum Institute, the partners will conduct an accelerated, integrated program of preclinical and clinical research to evaluate the antibodies for treatment of Covid-19. A Phase I clinical trial is expected to start early in 2021, the statement said.

Should the mAb candidates being developed be shown to be safe and efficacious, Merck and Serum Institute will help ensure that the therapy is rapidly and widely available and accessible, it added.

Joining the partners in this development effort are contract research and manufacturing firm Syngene International and bioengineering company ATUM, the statement said.

PTI

 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close